Multitarget-directed ligand-based therapy (MTDL) is taking precedence over conventional monotherapy, owing to the growing challenges of tumor recurrence and metastasis. Incorporation of multimodal imaging approaches to such MTDL could further enhance the safety and efficacy of these probes ultimately leading to quality-of-life enhancement for these cancer patients. On the contrary, despite the great wealth of information they provide, their synthesis is far from trivial. Herein we report the modular one-pot synthetic approach1 led to the development of a PET/MRI/OI radiotheranostic agent based on EDTA bisamide ligand with a pyridine-based fluorophore, with a strong affinity for multi-protein kinase targets as well as both transition and lanthanide-based radio/magneto metals. 64Cu radiolabelling of L1 in NaOAc & MES completed within 30 min. (pH 6, 40 °C), purified by HPLC. RCY evaluated by iTLC. Xenografts were generated by injecting B16-F10 cells (10 5) subcutaneously into the lateral flank of C57BL/6J mice. All mice received avg. dose of ~190µCi 64Cu radiolabeled tracer via I.V. injection. Two groups of WT mice underwent dynamic/static scans by PET/CT and PET/MRI (7T) at 1 & 24 h time points with 10 & 20 min acquisition respectively. Control mice injected with 64CuCl2 saline were imaged for comparison. Ex vivo biodistribution and Image-based quantification were also done. Very high tumor uptake (11.6 % ID/g, 24 h) from PET/MRI validated by PET/CT and ex vivo studies, Docking revealed inhibition of TSPO, FAP (allosteric), and EGFR (-6.9, -7.0, and 6.7 Kcal/mol), validated with respective co-crystallized ligands, commercial standards and by MD simulation. Therapeutic efficacy was recently validated in blocking studies with a commercial AURKB inhibitor (wherein 63% tumor regressino observed in 24 h). Excitation-emission optimized; 512 nm and 902 nm (PBS/DMSO). In physiological conditions, L1 was reproducibly radiolabelled with 68Ga, 56/52Mn in good yields (>94%) and evaluated in vitro/vivo. Apart from acting as transition elements-based PET/MRI/OI agents, application in theranostic pairs; 68Ga:90Y/177Lu-L1; 68Ga/225Ac-and fluorinated version (one-pot) of L1 as PET/MRI/OI Theranostic agents also envisaged.